Diagnostic ultrasound ( PDFDrive )

414 PART II Abdominal and Pelvic Sonography
94. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA
screening in the US prostate cancer mortality decline. Cancer Causes Control.
2008;19(2):175-181.
95. Alberts AR, Schoots IG, Roobol MJ. Prostate-speciic antigen-based prostate
cancer screening: past and future. Int J Urol. 2015;22(6):524-532.
96. Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer:
U.S. Preventive Services Task Force recommendation statement. Ann Intern
Med. 2012;157(2):120-134.
97. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer
mortality: results of the European Randomised Study of Screening for
Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):
2027-2035.
98. Andriole GL, Crawford ED, Grubb 3rd RL, et al. Prostate cancer screening
in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening
Trial: mortality results ater 13 years of follow-up. J Natl Cancer Inst.
2012;104(2):125-132.
99. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg
randomised population-based prostate-cancer screening trial. Lancet Oncol.
2010;11(8):725-732.
100. Herget KA, Patel DP, Hanson HA, et al. Recent decline in prostate cancer
incidence in the United States, by age, stage, and Gleason score. Cancer
Med. 2016;5(1):136-141.
101. Barry MJ, Nelson JB. Patients present with more advanced prostate cancer
since the USPSTF screening recommendations. J Urol. 2015;194(6):
1534-1536.
102. Kim EH, Andriole GL. Prostate-speciic antigen-based screening: controversy
and guidelines. BMC Med. 2015;13:61.
103. American Joint Committee on Cancer. Prostate cancer staging: American
Joint Committee on Cancer; 2010. Cited 21 May 2016. 7. Available from:
https://cancerstaging.org/references-tools/quickreferences/Documents/
ProstateSmall.pdf.
104. Crawford ED, Stone NN, Yu EY, et al. Challenges and recommendations
for early identiication of metastatic disease in prostate cancer. Urology.
2014;83(3):664-669.
105. Wollin DA, Makarov DV. Guideline of guidelines: imaging of localized
prostate cancer. BJU Int. 2015;116(4):526-530.
106. Cheng L, Montironi R, Bostwick DG, et al. Staging of prostate cancer.
Histopathology. 2012;60(1):87-117.
107. Jung AJ, Coakley FV, Shinohara K, et al. Local staging of prostate cancer:
comparative accuracy of T2-weighted endorectal MR imaging and transrectal
ultrasound. Clin Imaging. 2012;36(5):547-552.
108. Eisenberg ML, Cowan JE, Davies BJ, et al. he importance of tumor palpability
and transrectal ultrasonographic appearance in the contemporary clinical
staging of prostate cancer. Urol Oncol. 2011;29(2):171-176.
109. Hsu CY, Joniau S, Oyen R, et al. Transrectal ultrasound in the staging of
clinical T3a prostate cancer. Eur J Surg Oncol. 2007;33(1):79-82.
110. Kattan MW, Cuzick J, Fisher G, et al. Nomogram incorporating PSA
level to predict cancer-speciic survival for men with clinically localized
prostate cancer managed without curative intent. Cancer. 2008;112(1):
69-74.
111. Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict
pathologic stage of prostate cancer given prostate-speciic antigen level,
clinical stage, and biopsy Gleason score (Partin tables) based on cases from
2000 to 2005. Urology. 2007;69:1095-1101.
112. Andreou A, Whitten C, MacVicar D, et al. Imaging appearance of sarcomas
of the prostate. Cancer Imaging. 2013;13:228-237.
113. Epstein JI, Egevad L, Amin MB, et al. he 2014 International Society of
Urological Pathology (ISUP) Consensus Conference on Gleason Grading
of Prostatic Carcinoma: deinition of grading patterns and proposal for a
new grading system. Am J Surg Pathol. 2016;40(2):244-252.
114. Babaian RJ, Toi A, Kamoi K, et al. A comparative analysis of sextant
and an extended 11-core multisite directed biopsy strategy. J Urol.
2000;163(1):152-157.
115. Klotz L. Active surveillance for low-risk prostate cancer. Curr Urol Rep.
2015;16(4):24.
116. Bruinsma SM, Bangma CH, Carroll PR, et al. Active surveillance for prostate
cancer: a narrative review of clinical guidelines. Nat Rev Urol. 2016;
13(3):151-167.
117. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical
indings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
JAMA. 1994;271(5):368-374.
118. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome
ater radical prostatectomy, external beam radiation therapy, or interstitial
radiation therapy for clinically localized prostate cancer. JAMA.
1998;280(11):969-974.
119. Ondracek RP, Kattan MW, Murekeyisoni C. Validation of the Kattan
normogram for prostate cancer recurrence ater radical prostatectomy.
J Natl Compr Canc Netw. 2016;14(11):1395-1401.
120. Cooperberg MR, Freedland SJ, Pasta DJ, et al. Multiinstitutional validation
of the UCSF cancer of the prostate risk assessment for prediction of recurrence
ater radical prostatectomy. Cancer. 2006;107(10):2384-2391.
121. hompson I, hrasher JB, Aus G, et al. Guideline for the management of
clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6):
2106-2131.
122. Sanda MG, Kaplan ID. A 64-year-old man with low-risk prostate cancer:
review of prostate cancer treatment. JAMA. 2009;301(20):2141-2151.
123. van der Poel H, Klotz L, Andriole G, et al. Role of active surveillance and
focal therapy in low- and intermediate-risk prostate cancers. World J Urol.
2015;33(7):907-916.
124. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus
watchful waiting in early prostate cancer. N Engl J Med. 2005;352(19):
1977-1984.
125. Scarpato KR, Barocas DA. Use of mpMRI in active surveillance for localized
prostate cancer. Urol Oncol. 2016;34(7):320-325.
126. Lee F, Gray JM, McLeary RD, et al. Transrectal ultrasound in the diagnosis
of prostate cancer: location, echogenicity, histopathology, and staging.
Prostate. 1985;7(2):117-129.
127. Shinohara K, Scardino PT, Carter SS, Wheeler TM. Pathologic basis of the
sonographic appearance of the normal and malignant prostate. Urol Clin
North Am. 1989;16(4):675-691.
128. Engelbrecht MR, Barentsz JO, Jager GJ, et al. Prostate cancer staging using
imaging. BJU Int. 2000;86(Suppl. 1):123-134.
129. Shinohara K, Wheeler TM, Scardino PT. he appearance of prostate cancer
on transrectal ultrasonography: correlation of imaging and pathological
examinations. J Urol. 1989;142(1):76-82.
130. Lee HY, Lee HJ, Byun SS, et al. Classiication of focal prostatic lesions on
transrectal ultrasound (TRUS) and the accuracy of TRUS to diagnose prostate
cancer. Korean J Radiol. 2009;10(3):244-251.
131. Dyke CH, Toi A, Sweet JM. Value of random US-guided transrectal prostate
biopsy. Radiology. 1990;176(2):345-349.
132. Engelbrecht MR, Jager GJ, Laheij RJ, et al. Local staging of prostate cancer
using magnetic resonance imaging: a meta-analysis. Eur Radiol. 2002;12(9):
2294-2302.
133. Lawrentschuk N, Haider MA, Daljeet N, et al. ‘Prostatic evasive anterior
tumours’: the role of magnetic resonance imaging. BJU Int. 2010;105(9):
1231-1236.
134. Noh TI, Shin YS, Shim JS, et al. Are hypoechoic lesions on transrectal
ultrasonography a marker for clinically signiicant prostate cancer? Korean
J Urol. 2013;54(10):666-670.
135. Toi A, Neill MG, Lockwood GA, et al. he continuing importance of
transrectal ultrasound identiication of prostatic lesions. J Urol.
2007;177(2):516-520.
136. Ghai S, Eure G, Fradet V, et al. Assessing cancer risk in novel 29 MHz
micro-ultrasound images of the prostate: creation of the protocol of prostate
risk identiication using micro-ultrasound. J Urol. 2016;196(2):562-569.
137. Amiel GE, Slawin KM. Newer modalities of ultrasound imaging and treatment
of the prostate. Urol Clin North Am. 2006;33(3):329-337.
138. Mitterberger M, Pinggera GM, Pallwein L, et al. he value of threedimensional
transrectal ultrasonography in staging prostate cancer. BJU
Int. 2007;100(1):47-50.
139. Wijkstra H, Wink MH, de la Rosette JJ. Contrast speciic imaging in the
detection and localization of prostate cancer. World J Urol. 2004;22(5):
346-350.
140. Li Y, Tang J, Fei X, Gao Y. Diagnostic performance of contrast enhanced
ultrasound in patients with prostate cancer: a meta-analysis. Acad Radiol.
2013;20(2):156-164.